The per share price values Santarus at $2.6 billion, a 39 percent premium over the company’s 30-day trading average.
The acquisition will help Salix solidify its lead in the gastrointestinal market, and the companies’ combined revenue would be approximately $1.3 billion.
More Articles on Gastroenterology:
72% of Adults Have Not Sought Physician Help for GI Pain
Physicians Endoscopy Receives Cost Management Performance Award
Dr. Glenn Madokoro Gives GI Patients Access to Information Technology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
